Thank you for sharing!

Your article was successfully shared with the contacts you provided.
The new FDA initiative is meant to clear that backlog, speeding competition and the subsequent price drops. (Photo: Shutterstock)

Makers of copycat drugs will face pressure to bring down prices even more quickly as the U.S. Food and Drug Administration pushes to get more low-cost competition to market.

The FDA wants to prioritize certain generic-drug applications in an effort to drive down prices, which have drawn increasing scrutiny from lawmakers and the ire of President Donald Trump. The agency has its sights set on an incentive granted to drugmakers that are first to seek approval for a copy of a brand-name drug, according to a policy document released Thursday.

Complete your profile to continue reading and get FREE access to BenefitsPRO.com, part of your ALM digital membership.

Your access to unlimited BenefitsPRO.com content isn’t changing.
Once you are an ALM digital member, you’ll receive:

  • Critical BenefitsPRO.com information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events.
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com

Already have an account?


BenefitsPRO Broker Expo 2022Event

The premier educational and networking event for employee benefits brokers and agents.

Get More Information


Join BenefitsPRO

Don’t miss crucial news and insights you need to navigate the shifting employee benefits industry. Join BenefitsPRO.com now!

  • Unlimited access to BenefitsPRO.com - your roadmap to thriving in a disrupted environment
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
  • Exclusive discounts on BenefitsPRO.com and ALM events.

Already have an account? Sign In Now
Join BenefitsPRO
Live Chat

Copyright © 2022 ALM Media Properties, LLC. All Rights Reserved.